Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT00179907 : A Phase I/II Study of the Photon Radiosurgery System
PhasePhase 1/Phase 2
AgesMin: 2 Years Max: 32 Years
Inclusion Criteria:

- All patients must be between 2 and 32 yrs. of age. Patients who are pregnant or
lactating will not be included in this study.

- Patients must have an estimated survival time of > 3 months, and a Karnofsky
performance status of > 50% or and ECOG performance status of 0-2.

- Patient must have radiographic imaging evidence of tumor recurrence except for
glioblastoma multiforme.

- The recurrent tumor prior to irradiation with PRS must be < 4 cm.

- All patients must be > 3 weeks from cytotoxic chemotherapy, except if patient
received < 1 week of non-myelotoxic chemotherapy. In that case, patient may be
enrolled with permission of the principal investigator.

- All patients must be > 6 weeks from high dose chemotherapy with stem cell rescue.

- All patients must be > 3 weeks from prior radiation therapy.

- Patients with a history of prior irradiation will be included.

- Informed consent must be obtained prior to registration on the study.

Tumor Sites:

- Brain

- Spinal Cord

Tumor Types:

- Recurrent Medulloblastoma

- Recurrent Ependymoma (recurrence regardless of primary treatment)

- Recurrent Glioma

- Glioblastoma Multiforme

- Recurrent Craniopharyngioma

- Recurrent PNET (Primitive Neuroectodermal tumor)

- Recurrent Meningioma

- Recurrent Pineoblastoma

Tumor Size:

- < 4 cm in maximum diameter
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557